|
|
Line 8: |
Line 8: |
|
| |
|
| ==List of Chemotherapy Regimens== | | ==List of Chemotherapy Regimens== |
| {| class="wikitable"
| | |
| ! Name !! Components !! Example of uses, and other notes
| |
| |-
| |
| | '''[[7+3 regimen|7+3]]'''
| |
| | 7 days of Ara-C ([[cytarabine]]) plus 3 days of an [[anthracycline]] [[antibiotic]], either [[daunorubicin]] ([[DA regimen|DA]] or [[DAC regimen|DAC]] variant) or [[idarubicin]] ([[IA regimen|IA]] or [[IAC regimen|IAC]] variant)
| |
| | [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
| |
| |-
| |
| | '''[[ABVD]]''' <ref name="pmid54209">{{cite journal |author=Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C |title=Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP |journal=Cancer |volume=36 |issue=1 |pages=252–9 |year=1975 |month=July |pmid=54209 |doi= |url=}}</ref>
| |
| | [[Adriamycin]], [[bleomycin]], [[vinblastine]], [[dacarbazine]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | '''AC'''
| |
| | [[Adriamycin]]/[[Doxorubicin]], [[Cyclophosphamide]]
| |
| | [[Breast cancer]]
| |
| |-
| |
| | '''[[ACVBP-R regimen|ACVBP-R]]'''
| |
| | [[Adriamycin]], [[Cytoxan]], [[Vindesine]], [[Bleomycin]], [[Prednisone]], [[Rituximab]]
| |
| | [[Diffuse large B-cell lymphoma]]
| |
| |-
| |
| | '''ADOC''' <ref name="pmid10555755">{{cite journal |author=Berruti A, Borasio P, Gerbino A, ''et al.'' |title=Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience |journal=Br. J. Cancer |volume=81 |issue=5 |pages=841–5 |year=1999 |month=November |pmid=10555755 |pmc=2374302 |doi=10.1038/sj.bjc.6690773 |url=}}</ref>
| |
| | [[Doxorubicin]], [[cisplatin]], [[vincristine]], [[cyclophosphamide]]
| |
| | [[Thymic carcinoma]]
| |
| |-
| |
| | '''BACOD'''
| |
| | [[Bleomycin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[dexamethasone]]
| |
| | [[Non-Hodgkin's lymphoma]]
| |
| |-
| |
| | '''[[BEACOPP]]''' <ref name="pmid9850026">{{cite journal |author=Diehl V, Franklin J, Hasenclever D, ''et al.'' |title=BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group |journal=J. Clin. Oncol. |volume=16 |issue=12 |pages=3810–21 |year=1998 |month=December |pmid=9850026 |doi= |url=}}</ref>
| |
| | [[Bleomycin]], [[etoposide]], [[Adriamycin]] ([[doxorubicin]]), [[cyclophosphamide]], [[Oncovin]] ([[vincristine]]), [[procarbazine]], [[prednisone]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | '''BEP'''
| |
| | [[Bleomycin]], [[etoposide]], platinum ([[cisplatin]])
| |
| | [[Testicular cancer]], [[germ cell tumor]]s
| |
| |-
| |
| | '''CA'''
| |
| | [[cyclophosphamide]], [[doxorubicin]] (Adriamycin) (same as AC)
| |
| | [[Breast cancer]]
| |
| |-
| |
| | '''CAF'''
| |
| | [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[5-FU]]/[[Fluorouracil]]
| |
| | [[Breast cancer]]
| |
| |-
| |
| | '''CAPOX'''
| |
| | [[Capecitabine]] and [[oxaliplatin]]
| |
| | [[Colorectal cancer]]
| |
| |-
| |
| | '''CAV'''
| |
| | [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[Vincristine]]
| |
| | [[Lung cancer]]
| |
| |-
| |
| | '''CBV'''
| |
| | [[Cyclophosphamide]], [[BCNU|BCNU (carmustine)]], VP-16 ([[etoposide]])
| |
| | [[Lymphoma]]
| |
| |-
| |
| | '''CEOP-R'''
| |
| | [[Cyclophosphamide]], [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]] + rituximab
| |
| | [[Diffuse large B-cell lymphoma]] when patient cannot be given an anthracycline
| |
| |-
| |
| | '''CEPP'''
| |
| | [[Cyclophosphamide]], [[etoposide]], [[procarbazine]], [[prednisone]]
| |
| | [[Non-Hodgkin's lymphoma]]
| |
| |-
| |
| | '''ChlVPP/EVA'''
| |
| | [[Chlorambucil]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]], [[etoposide]], [[vinblastine]], [[doxorubicin]] (Adriamycin)
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | '''CHOEP'''
| |
| | [[Cyclophosphamide]], hydroxydaunorubicin ([[doxorubicin]]), [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]]
| |
| | [[Non-Hodgkin's lymphoma]]
| |
| |-
| |
| | '''[[CHOP]]'''
| |
| | [[Cyclophosphamide]], [[doxorubicin]] ([[hydroxydoxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| |
| | [[Non-Hodgkin's lymphoma]]
| |
| |-
| |
| | '''CHOP-R''' or '''R-CHOP'''
| |
| | CHOP + [[rituximab]]
| |
| | [[B cell]] [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''[[CHOP|COP]]''' or '''[[CHOP|CVP]]'''
| |
| | [[Cyclophosphamide]], [[vincristine]] (Oncovin), and [[prednisone]]
| |
| | Non-Hodgkin lymphoma in patients with history of [[cardiovascular disease]]
| |
| |-
| |
| | '''ClaPD'''
| |
| | [[Clarithromycin]], [[pomalidomide]], [[dexamethasone]]
| |
| | [[Multiple myeloma]]
| |
| |-
| |
| | '''[[CMF (therapy)|CMF]]'''
| |
| | [[Cyclophosphamide]], [[Methotrexate]], and [[5-Fluorouracil]]
| |
| | [[Breast Cancer]]
| |
| |-
| |
| | '''CMV'''
| |
| | [[Cisplatin]], [[methotrexate]], [[vinblastine]]
| |
| | Metastatic [[transitional cell carcinoma]] of the urinary tract
| |
| |-
| |
| | '''CODOX-M/IVAC''' <ref name="pmid12181251">{{cite journal |author=Mead GM, Sydes MR, Walewski J, ''et al.'' |title=An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study |journal=Ann. Oncol. |volume=13 |issue=8 |pages=1264–74 |year=2002 |month=August |pmid=12181251 |doi= |url=}}</ref>
| |
| | Cyclophosphamide, vincristine, doxorubicin, methotrexate (CODOX-M) + ifosfamide, etopiside (VP-16), cytarabine (Ara-C) (IVAC)
| |
| | [[Burkitt's lymphoma]]
| |
| |-
| |
| | '''[[COPP]]'''
| |
| | [[Cyclophosphamide]], Oncovin (vincristine), [[procarbazine]] and prednisone
| |
| | [[Non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''CT''' or '''TC'''
| |
| | [[Cyclophosphamide]] and [[docetaxel]] (Taxotere)
| |
| | [[Breast cancer]]
| |
| |-
| |
| | '''CTD'''
| |
| | [[Cyclophosphamide]], [[thalidomide]], [[dexamethasone]]
| |
| | [[AL amyloidosis]]
| |
| |-
| |
| | '''CVAD'''
| |
| | [[Cyclophosphamide]], [[vincristine]], [[doxorubicin]] (Adriamycin), [[dexamethasone]]
| |
| | Aggressive [[non-Hodgkin lymphoma]], [[lymphoblastic lymphoma]], some forms of [[leukemia]]
| |
| |-
| |
| | '''CyBorD'''
| |
| | [[Cyclophosphamide]], [[bortezomib]], [[dexamethasone]]
| |
| | [[Multiple myeloma]], [[AL amyloidosis]]
| |
| |-
| |
| | '''DA-EPOCH''' <ref name="pmid11929754">{{cite journal |author=Wilson WH, Grossbard ML, Pittaluga S, ''et al.'' |title=Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |journal=Blood |volume=99 |issue=8 |pages=2685–93 |year=2002 |month=April |pmid=11929754 |doi= |url=}}</ref>
| |
| | Dose-adjusted [[Etopiside]], [[prednisone]], [[vincristine]] (Oncovin), [[Cyclophosphamide]] and doxorubicin
| |
| | Newly diagnosed, aggressive [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''DCEP'''
| |
| | [[Dexamethasone]], [[cyclophosphamide]], [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| |
| | [[Multiple myeloma]]
| |
| |-
| |
| | '''DHAP''' <ref name="pmid3334893">{{cite journal |author=Velasquez WS, Cabanillas F, Salvador P, ''et al.'' |title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) |journal=Blood |volume=71 |issue=1 |pages=117–22 |year=1988 |month=January |pmid=3334893 |doi= |url=}}</ref>
| |
| | Dexamethasone, cytarabine (high-dose ARA-C), cisplatin
| |
| | Recurrent or refractory [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''DHAX-R''' <ref name="pmid20709662">{{cite journal |author=Lignon J, Sibon D, Madelaine I, ''et al.'' |title=Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |journal=Clin Lymphoma Myeloma Leuk |volume=10 |issue=4 |pages=262–9 |year=2010 |month=August |pmid=20709662 |doi=10.3816/CLML.2010.n.055 |url=}}</ref>
| |
| | Dexamethasone, cytarabine, oxaliplatin and rituximab
| |
| | Relapsed or refractory B-cell [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''DICE'''
| |
| | [[Dexamethasone]], [[ifosfamide]], [[cisplatin]], [[etoposide]] (VP-16)
| |
| | Aggressive relapsed [[lymphomas]], progressive [[neuroblastoma]]
| |
| |-
| |
| | '''DT-PACE'''
| |
| | [[Dexamethasone]], [[thalidomide]], [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| |
| | [[Multiple myeloma]]
| |
| |-
| |
| | '''EC'''
| |
| | [[Epirubicin]], [[Cyclophosphamide]]
| |
| | [[Breast cancer]]
| |
| |-
| |
| | '''ECF'''
| |
| | [[Epirubicin]], [[cisplatin]], [[fluorouracil]]
| |
| | [[Gastric cancer]] and [[oesophageal cancer]]
| |
| |-
| |
| | '''EOX'''
| |
| | [[Epirubicin]], [[oxaliplatin]], [[capecitabine]]
| |
| | [[Esophageal cancer]], [[gastric cancer]]
| |
| |-
| |
| | '''EP'''
| |
| | [[Etoposide]], [[platinum-based antineoplastic|platinum agent]]
| |
| | [[testicular cancer]], [[germ cell tumor]]s
| |
| |-
| |
| | '''EPOCH'''
| |
| | [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | '''EPOCH-R''' or '''R-EPOCH'''
| |
| | [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]] plus [[rituximab]]
| |
| | [[B cell]] [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | '''ESHAP'''
| |
| | [[Etopiside]], methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin
| |
| | Relapsed or refractory [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''ESHAP-R''' or '''R-ESHAP'''
| |
| | [[etoposide]], [[methylprednisolone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]] plus [[rituximab]]
| |
| | [[Non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''FAM'''
| |
| | [[Fluorouracil]], [[doxorubicin]] (Adriamycin), [[mitomycin]]
| |
| | Metastatic small bowel adenocarcinoma
| |
| |-
| |
| | '''FCM''' or '''FMC'''
| |
| | [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | '''FCM-R''' or '''R-FCM''' or '''R-FMC''' or '''FMC-R'''
| |
| | [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] plus [[rituximab]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | '''FM'''
| |
| | [[Fludarabine]], [[mitoxantrone]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | '''FMR'''
| |
| | [[Fludarabine]], [[mitoxantrone]], and [[rituximab]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | '''FEC'''
| |
| | [[Fluorouracil]] (5-FU), [[epirubicin]], [[cyclophosphamide]]
| |
| | [[Breast cancer]]
| |
| |-
| |
| | '''FL'''
| |
| | [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]])
| |
| | [[Colorectal cancer]]
| |
| |-
| |
| | '''FLAG'''
| |
| | [[Fludarabine]], [[cytarabine]], [[G-CSF]]
| |
| | Relapsed or [refractory [[acute myelogenous leukemia]]
| |
| |-
| |
| | '''FLAG-Ida''' or '''FLAG-IDA''' or '''IDA-FLAG''' or '''Ida-FLAG'''
| |
| | [[Fludarabine]], [[cytarabine]], [[idarubicin]], [[G-CSF]]
| |
| | Relapsed or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
| |
| |-
| |
| | '''FLAG-Mito''' or '''FLAG-MITO''' or '''Mito-FLAG''' or '''MITO-FLAG''' or '''FLAMG'''
| |
| | [[Mitoxantrone]], [[fludarabine]], [[cytarabine]], [[G-CSF]]
| |
| | Relapsed or refractory [[acute myelogenous leukemia]]
| |
| |-
| |
| | '''FLAMSA'''
| |
| | [[Fludarabine]], [[cytarabine]], [[amsacrine]]
| |
| | [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
| |
| |-
| |
| | '''FLAMSA-BU''' or '''FLAMSA-Bu'''
| |
| | [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[busulfan]]
| |
| | [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
| |
| |-
| |
| | '''FLAMSA-MEL''' or '''FLAMSA-Mel'''
| |
| | [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[melphalan]]
| |
| | [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
| |
| |-
| |
| | '''FN-D''' <ref name="pmid8648382">{{cite journal |author=McLaughlin P, Hagemeister FB, Romaguera JE, ''et al.'' |title=Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma |journal=J. Clin. Oncol. |volume=14 |issue=4 |pages=1262–8 |year=1996 |month=April |pmid=8648382 |doi= |url=}}</ref>
| |
| | Fludarabine, mitoxantrone (Novantrone), dexamethasone
| |
| | Recurrent or refractory indolent [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''FOLFIRI''' <ref name="pmid10744089">{{cite journal |author=Douillard JY, Cunningham D, Roth AD, ''et al.'' |title=Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial |journal=Lancet |volume=355 |issue=9209 |pages=1041–7 |year=2000 |month=March |pmid=10744089 |doi= |url=}}</ref>
| |
| | Leucovorin, infusional fluorouracil, irinotecan
| |
| | Metastatic [[colorectal cancer]]
| |
| |-
| |
| | '''FOLFIRINOX'''
| |
| | [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[irinotecan]], [[oxaliplatin]]
| |
| | [[Pancreatic cancer]]
| |
| |-
| |
| | '''[[FOLFOX]]'''
| |
| | [[Fluorouracil]], [[leucovorin]] ([[folinic acid]]), and [[oxaliplatin]]
| |
| | [[Colorectal cancer]]
| |
| |-
| |
| | '''GVD'''
| |
| | [[Gemcitabine]], [[vinorelbine]], pegylated liposomal [[doxorubicin]]
| |
| | [[Hodgkin lymphoma]]
| |
| |-
| |
| | '''GemOx'''
| |
| | [[Gemcitabine]], [[oxaliplatin]]
| |
| | [[Non-Hodgkin's lymphoma]]
| |
| |-
| |
| | '''GemOx-R'''
| |
| | [[Gemcitabine]], [[oxaliplatin]], [[rituximab]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | '''HYPER-CVAD''' <ref name="pmid10561310">{{cite journal |author=Thomas DA, Cortes J, O'Brien S, ''et al.'' |title=Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia |journal=J. Clin. Oncol. |volume=17 |issue=8 |pages=2461–70 |year=1999 |month=August |pmid=10561310 |doi= |url=}}</ref>
| |
| | Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone ([[Decadron]])
| |
| | [[Burkitt's lymphoma]]
| |
| |-
| |
| | '''IA''' or '''IAC'''
| |
| | [[Idarubicin]] x 3 days plus Ara-C ([[cytarabine]]) x 7 days, a variant of classical [[7+3 regimen|7+3]] regimen
| |
| | [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
| |
| |-
| |
| | '''ICE''' <ref name="pmid10577849">{{cite journal |author=Moskowitz CH, Bertino JR, Glassman JR, ''et al.'' |title=Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3776–85 |year=1999 |month=December |pmid=10577849 |doi= |url=}}</ref>'
| |
| | Ifosfamide, carboplatin, etopiside
| |
| | Relapsed or primary refractory [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''ICE-R'''
| |
| | ICE + [[rituximab]]
| |
| | Relapsed or primary refractory [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''IFL''' <ref name="pmid11006366">{{cite journal |author=Saltz LB, Cox JV, Blanke C, ''et al.'' |title=Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group |journal=N. Engl. J. Med. |volume=343 |issue=13 |pages=905–14 |year=2000 |month=September |pmid=11006366 |doi= |url=}}</ref>
| |
| | [[Irinotecan]], [[bolus fluorouracil]] and leucovorin
| |
| | Metastatic [[Colorectal cancer|colorectal cancer]]
| |
| |-
| |
| | '''m-BACOD'''
| |
| | [[Methotrexate]], [[bleomycin]], doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone ([[Decadron]])
| |
| | [[Non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''MACOP-B''' <ref name="pmid2580468">{{cite journal |author=Klimo P, Connors JM |title=MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma |journal=Ann. Intern. Med. |volume=102 |issue=5 |pages=596–602 |year=1985 |month=May |pmid=2580468 |doi= |url=}}</ref>
| |
| | [[Methotrexate]], [[leucovorin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| |
| | Non-Hodgkin lymphoma
| |
| |-
| |
| | '''MINE'''
| |
| | [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]]
| |
| | [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
| |
| |-
| |
| | '''MINE-R''' or '''R-MINE'''
| |
| | [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]] plus [[rituximab]]
| |
| | [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
| |
| |-
| |
| | '''Mini-BEAM''' <ref name="pmid7844600">{{cite journal |author=Colwill R, Crump M, Couture F, ''et al.'' |title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |journal=J. Clin. Oncol. |volume=13 |issue=2 |pages=396–402 |year=1995 |month=February |pmid=7844600 |doi= |url=}}</ref>
| |
| | Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan
| |
| | Hodgkin's lymphoma ([[Salvage therapy]], pre-[[Stem cell transplantation|transplant]])
| |
| |-
| |
| | '''[[MOPP (medicine)|MOPP]]'''
| |
| | [[Mechlorethamine]], [[vincristine]] ([[oncovin]]), [[procarbazine]], [[prednisone]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | '''MVAC''' <ref name="pmid11001674">{{cite journal |author=von der Maase H, Hansen SW, Roberts JT, ''et al.'' |title=Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study |journal=J. Clin. Oncol. |volume=18 |issue=17 |pages=3068–77 |year=2000 |month=September pmid=11001674 |doi= |url=}}</ref>
| |
| | Methotrexate, vinblastine, doxorubicin, cisplatin
| |
| | [[Bladder cancer]]
| |
| |-
| |
| | '''NABTT''' <ref name="pmid11835382">{{cite journal |author=Herrlinger U, Schabet M, Brugger W, ''et al.'' |title=German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma |journal=Ann. Neurol. |volume=51 |issue=2 |pages=247–52 |year=2002 |month=February |pmid=11835382 |doi= |url=}}</ref>
| |
| | Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin
| |
| | [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
| |
| |-
| |
| | '''PCV''' <ref name="pmid7407756">{{cite journal |author=Levin VA, Edwards MS, Wright DC, ''et al.'' |title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors |journal=Cancer Treat Rep |volume=64 |issue=2-3 |pages=237–44 |year=1980 |pmid=7407756 |doi= |url=}}</ref>
| |
| | [[Procarbazine]], [[lomustine]] (CCNU), [[vincristine]]
| |
| | [[Brain tumors]]
| |
| |-
| |
| | '''ProMACE-MOPP'''
| |
| | [[Methotrexate]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]] + [[MOPP (medicine)|MOPP]]
| |
| | Non-Hodgkin lymphoma
| |
| |-
| |
| | '''ProMACE-CytaBOM'''
| |
| | [[Prednisone]], [[doxorubicin]] ([[adriamycin]]), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine ]](Oncovin), [[methotrexate]], [[leucovorin]]
| |
| | [[Non-Hodgkin lymphoma]]
| |
| |-
| |
| | '''RdC''' or '''RCD'''
| |
| | [[Lenalidomide]] (Revlimid), [[dexamethasone]], [[cyclophosphamide]]
| |
| | [[Multiple myeloma]]
| |
| |-
| |
| | '''R-DHAOx''' <ref name="urlScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect
| |
| in previously treated patients with follicular non-Hodgkins lymphoma">{{cite web |url=http://dx.doi.org/10.1016/j.biopha.2009.11.001 |title=ScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma |format= |work= |accessdate=}}</ref>
| |
| | Rituximab, dexamethasone, high-dose cytarabine, [[oxaliplatin]]
| |
| | Previously treated [[follicular lymphoma]]
| |
| |-
| |
| | '''R-FCM'''
| |
| | [[Rituximab]], [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | '''RTOG 93-10''' <ref name="pmid12488408">{{cite journal |author=DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ |title=Combination chemotherapy and radiotherapy for primary central nervous system
| |
| | lymphoma: Radiation Therapy Oncology Group Study 93-10 |journal=J. Clin. Oncol. |volume=20 |issue=24 |pages=4643–8 |year=2002 |month=December |pmid=12488408 |doi= |url=}}</ref>
| |
| | Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin
| |
| | [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
| |
| |-
| |
| | '''RVD'''
| |
| | [[Lenalidomide]] (Revlimid), [[bortezomib]] (Velcade), [[dexamethasone]]
| |
| | [[Multiple myeloma]]
| |
| |-
| |
| | '''SMILE'''
| |
| | Steroid (dexamethasone/prednisolone), methotrexate, ifosfamide, L-asparaganase, etopisode
| |
| | Advanced refractory NK/T-cell lymphoma and leukemia
| |
| |-
| |
| | '''[[Stanford V]]''' <ref name="pmid7537796">{{cite journal |author=Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ |title=Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report |journal=J. Clin. Oncol. |volume=13 |issue=5 |pages=1080–8 |year=1995 |month=May |pmid=7537796 |doi= |url=}}</ref>
| |
| | [[Doxorubicin]] ([[Adriamycin]]), [[mechlorethamine]], [[bleomycin]], vinblastine, vincristine (Oncovin), etoposide ([[VP-16]]), prednisone
| |
| | Hodgkin's lymphoma
| |
| |-
| |
| | '''TAC''' <ref name="pmid11208821">{{cite journal |author=Nabholtz JM, Mackey JR, Smylie M, ''et al.'' |title=Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer |journal=J. Clin. Oncol. |volume=19 |issue=2 |pages=314–21 |year=2001 |month=January |pmid=11208821 |doi= |url=}}</ref>
| |
| | Docetaxel, doxorubicin, cyclophosphamide
| |
| | Metastatic breast cancer
| |
| |-
| |
| | '''TAP''' <ref name="pmid15169803">{{cite journal |author=Fleming GF, Brunetto VL, Cella D, ''et al.'' |title=Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study |journal=J. Clin. Oncol. |volume=22 |issue=11 |pages=2159–66 |year=2004 |month=June |pmid=15169803 |doi=10.1200/JCO.2004.07.184 |url=}}</ref>
| |
| | Paclitaxel, doxorubicin, cisplatin
| |
| | [[Endometrial cancer]]
| |
| |-
| |
| | '''TCH'''
| |
| | [[Paclitaxel]] (Taxol), [[carboplatin]], [[trastuzumab]] (Herceptin)
| |
| | [[Breast cancer]] with positive [[HER2/neu]] receptor
| |
| |-
| |
| | '''Thal/Dex'''
| |
| | [[Thalidomide]], dexamethasone
| |
| | Multiple myeloma
| |
| |-
| |
| | '''TIP'''
| |
| | [[Paclitaxel]] (Taxol), [[ifosfamide]], platinum agent [[cisplatin|cisplatin (Platinol)]]
| |
| | [[Testicular cancer]], [[germ cell tumor]]s in salvage therapy
| |
| |-
| |
| | '''Treanda + Rituxan'''
| |
| | [[Bendamustine]], [[Rituximab]]
| |
| | Indolent and [[mantle cell lymphoma|mantle cell lymphomas]]
| |
| |-
| |
| | '''VAC'''
| |
| | [[Vincristine]], [[actinomycin]], [[cyclophosphamide]]
| |
| | [[Rhabdomyosarcoma]]
| |
| |-
| |
| | '''VAD'''
| |
| | [[Vincristine]], [[Adriamycin]] (doxorubicin), [[dexamethasone]]
| |
| | [[Multiple myeloma]]
| |
| |-
| |
| | '''VAPEC-B'''
| |
| | [[Vincristine]], [[doxorubicin]] (Adriamycin), [[prednisone]], [[etoposide]], [[cyclophosphamide]], [[bleomycin]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | '''VCAP-AMP-VECP''' <ref name="pmid17968021">{{cite journal |author=Tsukasaki K, Utsunomiya A, Fukuda H, ''et al.'' |title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 |journal=J. Clin. Oncol. |volume=25 |issue=34 |pages=5458–64 |year=2007 |month=December |pmid=17968021 |doi=10.1200/JCO.2007.11.9958 |url=}}</ref>
| |
| | Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, [[ranimustine]], and prednisone (AMP)-- [[vindesine]], etoposide, carboplatin, and prednisone (VECP)
| |
| | Adult T-cell leukemia-lymphoma (ATLL)
| |
| |-
| |
| | '''VeIP''' <ref name="pmid9667270">{{cite journal |author=Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH |title=Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor |journal=J. Clin. Oncol. |volume=16 |issue=7 |pages=2500–4 |year=1998 |month=July |pmid=9667270 |doi= |url=}}</ref>
| |
| | Vinblastine, ifosfamide, cisplatin
| |
| | [[Testicular cancer]]
| |
| |-
| |
| | '''VIP''' <ref name="pmid9552027">{{cite journal |author=Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ |title=Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study |journal=J. Clin. Oncol. |volume=16 |issue=4 |pages=1287–93 |year=1998 |month=April |pmid=9552027 |doi= |url=}}</ref>
| |
| | Etopiside, ifosfamide, cisplatin
| |
| | [[Testicular cancer]]
| |
| |-
| |
| | '''VTD-PACE'''
| |
| | [[Bortezomib]] (Velcade), [[thalidomide]], [[dexamethasone]] plus [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| |
| | [[Multiple myeloma]]
| |
| |}
| |
|
| |
|
| ==References== | | ==References== |